194 related articles for article (PubMed ID: 25843431)
1. Lenalidomide in multiple myeloma.
Kim Y; Schmidt-Wolf IG
Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
[TBL] [Abstract][Full Text] [Related]
2. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Ríos-Tamayo R; Martín-García A; Alarcón-Payer C; Sánchez-Rodríguez D; de la Guardia AMDVD; García Collado CG; Jiménez Morales A; Jurado Chacón M; Cabeza Barrera J
Drug Des Devel Ther; 2017; 11():2399-2408. PubMed ID: 28860711
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Srkalovic G; Hussein M
Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
7. Second malignancies in multiple myeloma; emerging patterns and future directions.
Maclachlan K; Diamond B; Maura F; Hillengass J; Turesson I; Landgren CO; Kazandjian D
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101144. PubMed ID: 32139010
[TBL] [Abstract][Full Text] [Related]
8. Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma.
Rath C; Yoo C; Cheplowitz H; Lo M; Young R; Guglielmo J; Saunders IM; Banerjee R; Young R; Kumar A; Chung A; Rosenberg AS; Costello C; Fine J; Wilson M; Patel N; Banez MT
J Oncol Pharm Pract; 2023 Oct; 29(7):1715-1724. PubMed ID: 36731514
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies for multiple myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
[No Abstract] [Full Text] [Related]
10. Near-infrared light controlled protein degradation by photo-caged lenalidomide and pomalidomide.
Zhu Y; Yan X; Shi Y; Liu B; Huang W; Chu L
Bioorg Chem; 2024 Feb; 143():107050. PubMed ID: 38163423
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.
Ononogbu O; Akindele O; Yazdanfard S; Fatima B; Abughosh S; Trivedi MV
Support Care Cancer; 2024 Jun; 32(7):407. PubMed ID: 38833106
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide and its analogues in the treatment of Multiple Myeloma.
Latif T; Chauhan N; Khan R; Moran A; Usmani SZ
Exp Hematol Oncol; 2012 Sep; 1(1):27. PubMed ID: 23210501
[TBL] [Abstract][Full Text] [Related]
13. A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials.
Fleischer A; Zapf L; Allgaier J; Jordan K; Gelbrich G; Pryss R; Schobel J; Bittrich M; Einsele H; Kortüm M; Maatouk I; Weinhold N; Rasche L
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12897-12902. PubMed ID: 37466796
[No Abstract] [Full Text] [Related]
14. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
15. The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer.
Jin JO; Puranik N; Bui QT; Yadav D; Lee PC
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502538
[TBL] [Abstract][Full Text] [Related]
16. Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.
Murayama N; Suemizu H; Uehara S; Kusama T; Mitsui M; Kamiya Y; Shimizu M; Guengerich FP; Yamazaki H
J Toxicol Sci; 2018; 43(6):369-375. PubMed ID: 29877213
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
